US 12,405,276 B2
Methods of detecting septic arthritis, transient synovitis and osteomyelitis
Scott Luhmann, St. Louis, MO (US)
Assigned to Washington University, St. Louis, MO (US)
Appl. No. 17/432,700
Filed by Washington University, St. Louis, MO (US)
PCT Filed Feb. 21, 2020, PCT No. PCT/US2020/019352
§ 371(c)(1), (2) Date Aug. 20, 2021,
PCT Pub. No. WO2020/172622, PCT Pub. Date Aug. 27, 2020.
Claims priority of provisional application 62/808,598, filed on Feb. 21, 2019.
Prior Publication US 2022/0187314 A1, Jun. 16, 2022
Int. Cl. G01N 33/74 (2006.01); G01N 33/68 (2006.01)
CPC G01N 33/6893 (2013.01) [G01N 33/6869 (2013.01); G01N 33/6887 (2013.01); G01N 33/74 (2013.01); G01N 2333/495 (2013.01); G01N 2333/5418 (2013.01); G01N 2333/5753 (2013.01); G01N 2333/78 (2013.01); G01N 2800/102 (2013.01)] 7 Claims
OG exemplary drawing
 
1. A method of identifying and treating a subject having septic arthritis, the method comprising:
i) measuring expression levels of proteins comprising TGFα, IL-7, IL-33 and IL-28A in a blood sample obtained from the subject;
ii) determining a septic arthritis protein signature based on the expression levels of the proteins in step (i); and
iii) assessing septic arthritis occurrence or severity of the subject based on the protein signature determined in step (ii); and
iv) administering a therapeutically effective amount of a therapeutic agent to the subject based on the septic arthritis occurrence or severity determined in step (iii), wherein the therapeutic agent is selected from the group consisting of an antibiotic, an antiviral agent, and an anti-inflammatory agent.